Baili Tianheng: Rulongconilutamab for Injection Included in the National Medical Insurance Catalog

Baili Tianheng announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the "National Drug Catalog for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance" on November 14, 2026, effective from January 1, 2027. The company's wholly-owned subsidiary, Chengdu Baili Duote Biopharmaceutical Co., Ltd., independently developed the injectable "Lunconilontamab," which passed the national medical insurance negotiation in its first year on the market and was successfully included in the catalog. Its medical insurance payment management classification is Category B negotiated drug during the agreement period, with the payment scope limited to adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least second-line systemic chemotherapy. The agreement is valid from January 1, 2027, to December 31, 2028.